LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Medtronic PLC

Cerrado

SectorSanidad

87.41 0.59

Resumen

Variación precio

24h

Actual

Mínimo

87.07

Máximo

87.41

Métricas clave

By Trading Economics

Ingresos

16M

1.3B

Ventas

-111M

8.3B

P/B

Media del Sector

23.197

51.198

BPA

1.62

Rentabilidad por dividendo

3.39

Margen de beneficios

15.605

Empleados

95,000

EBITDA

-42M

2.4B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+10.07% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.39%

2.40%

Próximas Ganancias

19 ago 2025

Fecha Próximo Dividendo

11 jul 2025

Próxima Fecha de Ex Dividendo

27 jun 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-13B

107B

Apertura anterior

86.82

Cierre anterior

87.41

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

68 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Medtronic PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 may 2025, 11:38 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

18 feb 2025, 12:24 UTC

Ganancias

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

21 may 2025, 17:23 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

21 may 2025, 11:39 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

21 may 2025, 10:52 UTC

Ganancias

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

21 may 2025, 10:51 UTC

Ganancias

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

21 may 2025, 10:50 UTC

Ganancias

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

21 may 2025, 10:49 UTC

Ganancias

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

21 may 2025, 10:49 UTC

Ganancias

Medtronic Names Michael Carter Sr VP, President of Cranial, Spinal Technologies >MDT

21 may 2025, 10:48 UTC

Ganancias

Medtronic Names Skip Kiil Exec VP, President of Cardiovascular Portfolio >MDT

21 may 2025, 10:48 UTC

Ganancias

Medtronic: Sean Salmon, Exec VP and President of, Cardiovascular Portfolio Leaving >MDT

21 may 2025, 10:47 UTC

Ganancias

Medtronic Raises Quarterly Dividend to 71c From 70c >MDT

21 may 2025, 10:45 UTC

Adquisiciones, fusiones, absorciones

Medtronic: Preferred Path of Initial Public Offering, Subsequent Split-Off >MDT

21 may 2025, 10:45 UTC

Ganancias

Medtronic Reports Strong Finish To Its Fiscal Year With Its Fourth Quarter Financial Results; Announces Dividend Increase >MDT

21 may 2025, 10:45 UTC

Ganancias

Medtronic 4Q Net $1.06B >MDT

21 may 2025, 10:45 UTC

Ganancias

Medtronic 4Q Medical Surgical Portfolio Rev $2.21B >MDT

21 may 2025, 10:45 UTC

Ganancias

Medtronic 4Q Neuroscience Portfolio Rev $2.62B >MDT

21 may 2025, 10:45 UTC

Ganancias

Medtronic 4Q Diabetes Rev $728M >MDT

21 may 2025, 10:45 UTC

Ganancias

Medtronic 4Q Organic Revenue Up 5.4% >MDT

21 may 2025, 10:45 UTC

Ganancias

Medtronic 4Q Adj EPS $1.62 >MDT

21 may 2025, 10:45 UTC

Ganancias

Medtronic 4Q EPS 82c >MDT

21 may 2025, 10:45 UTC

Ganancias

Medtronic 4Q Cardiovascular Portfolio Rev $3.34B >MDT

21 may 2025, 10:45 UTC

Ganancias

Medtronic 4Q Sales $8.93B >MDT

21 may 2025, 09:00 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Medtronic to Separate Diabetes Business as Stand-Alone Company -- WSJ

21 may 2025, 09:00 UTC

Adquisiciones, fusiones, absorciones

Medtronic to Separate Diabetes Business, Sources Say -- WSJ

21 may 2025, 09:00 UTC

Adquisiciones, fusiones, absorciones

Medtronic's Separation of Diabetes Business to Finish Within 18 Months, Sources Say -- WSJ

21 may 2025, 09:00 UTC

Adquisiciones, fusiones, absorciones

Medtronic Diabetes Business Sales Totaled Nearly $2.5B in 2024 -- WSJ

27 feb 2025, 10:30 UTC

Principales Noticias

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18 feb 2025, 11:47 UTC

Ganancias

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18 feb 2025, 11:46 UTC

Ganancias

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

Comparación entre iguales

Cambio de precio

Medtronic PLC previsión

Precio Objetivo

By TipRanks

10.07% repunte

Estimación a 12 Meses

Media 95.76 USD  10.07%

Máximo 109 USD

Mínimo 87 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Medtronic PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

21 ratings

11

Comprar

10

Mantener

0

Vender

Puntuación técnica

By Trading Central

83.26 / 84.875Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

68 / 380 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.